Two Near-Term NDAs & Robust Drug Development Pipeline

	Indication / Target	Program	Trial Name / Collaborator	Preclinical	Phase 1	Phase 2	Phase 3	Commercial Rights[1]	Status/Next Milestone
Late stage	CIN (All cancer, all chemo)	Plinabulin + pegfilgrastim	PROTECTIVE-1 & PROTECTIVE-2	Phase 3 primary endpoint met in pivotal data announced November 2020				Global	China and U.S. NDA submission in **March 2021;** currently under regulatory review
Late stage	NSCLC (2nd/3rd line)	Plinabulin + docetaxel	DUBLIN-3	Phase 3 second interim analysis completed				Global	Global Final topline Phase 3 data Mid **2021**
Triple Combo IO (IIT)	SCLC	Plinabulin + nivolumab + ipilimumab	10 US sites, including Rutgers University as lead site					Global	Phase 1 completed
Triple Combo IO (IIT)	Multi-cancer (2nd/3rd line)	Plinabulin + PD-1/PD-L1 + radiation/chemo	THE UNIVERSITY OF TEXAS MD Anderson Cancer Center					Global	Initiate Phase 1 in 7 cancers **Q2 2021**
Investigator-initiated IO	Oral T cell co-stimulator	BPI-002						Global	
Investigator-initiated IO	IKK inhibitor	BPI-003						Global	
Investigator-initiated IO	Oral neo-antigen generator	BPI-004						Global	
SEED Therapeutics	KRAS and additional targets	Targeted Protein degradation (TPD, molecule glue platform)	SEED THERAPEUTICS					Global	Potential additional partnerships
SEED Therapeutics	Multiple		Lilly						$800M collaboration

[1]Global rights to Plinabulin ex-China. 58% ownership of Chinese subsidiary, Dalian Wanchunbulin Pharmaceuticals Ltd., which owns Chinese rights to Plinabulin. BeyondSpring owns 100% of global rights to Plinabulin. SEED Therapeutics is a ~60%-owned BeyondSpring subsidiary.